Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.
暂无分享,去创建一个
P. Teirstein | M. Price | E. Topol | C. Cannon | D. Kandzari | D. Angiolillo | J. Tanguay | P. Berger
[1] Betti Giusti,et al. Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up , 2009, Circulation.
[2] J. Collet,et al. Abstract 4021: Clopidogrel 150 Mg/day to Overcome Low Responsiveness in Patients Undergoing Elective Percutaneous Coronary Intervention. Results from the Vasp-02 Randomized Study , 2008 .
[3] G. Patti,et al. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. , 2008, Journal of the American College of Cardiology.
[4] H. Hod,et al. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. , 2008, The American journal of cardiology.
[5] Matthew J Price,et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European Heart Journal.
[6] J. Tardif,et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. , 2008, Journal of the American College of Cardiology.
[7] K. Winters,et al. The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration , 2008, Thrombosis and Haemostasis.
[8] Jeffrey L. Anderson,et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. , 2008, Journal of the American College of Cardiology.
[9] Jeffrey L. Anderson,et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[10] Li Zhang,et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. , 2008, European heart journal.
[11] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[12] A. Gori,et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high‐risk coronary artery disease patients , 2007, Journal of thrombosis and haemostasis : JTH.
[13] A. Gori,et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. , 2007, Journal of the American College of Cardiology.
[14] P. Serruys,et al. Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.
[15] C. Macaya,et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. , 2007, Journal of the American College of Cardiology.
[16] P. Gurbel,et al. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? , 2007, Journal of the American College of Cardiology.
[17] D. Angiolillo,et al. Randomized Comparison of a High Clopidogrel Maintenance Dose in Patients With Diabetes Mellitus and Coronary Artery Disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) Study , 2007, Circulation.
[18] F. Neumann,et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. , 2006, Journal of the American College of Cardiology.
[19] V. Serebruany,et al. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. , 2006, Methods and findings in experimental and clinical pharmacology.
[20] Joseph P Ornato,et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update the 2001 Guidelines for Percutaneous Coronary Intervention , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[21] P. Gurbel,et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. , 2005, Journal of the American College of Cardiology.
[22] P. Gurbel,et al. Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets: Results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) Study , 2005, Circulation.
[23] P. Gurbel,et al. The difference between clopidogrel responsiveness and posttreatment platelet reactivity. , 2005, Thrombosis research.
[24] A. Kastrati,et al. Loading With 600 mg Clopidogrel in Patients With Coronary Artery Disease With and Without Chronic Clopidogrel Therapy , 2004, Circulation.
[25] S. Yusuf,et al. Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.
[26] S. Pocock,et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. , 1999, The New England journal of medicine.
[27] S. Pocock,et al. A Clinical Trial Comparing Three Antithrombotic-Drug Regimens after Coronary-Artery Stenting , 1998 .
[28] Frans Van de Werf,et al. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.